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Abstract
Background: In non-small cell lung cancer (NSCLC) patients off erlotinib therapy, positron emission tomography
(PET) using [11C]erlotinib distinguished epidermal growth factor receptor (EGFR) mutations from wild-type EGFR.
However, tumor uptake of [11C]erlotinib during erlotinib therapy is unknown. Therefore, the aims of this study were
to evaluate tumor [11C]erlotinib uptake in NSCLC patients both on and off erlotinib therapy, to evaluate the effect
of erlotinib therapy on tumor perfusion and its correlation to tumor [11C]erlotinib uptake, and also, to investigate
simplified uptake parameters using arterial and venous blood samples.
Methods: Ten patients were to be scanned twice with a 1–2-week interval, i.e., on (E+) and off (E−) erlotinib
therapy. Each procedure consisted of a low-dose CT scan, a 10-min dynamic [15O]H2O PET scan, and a 60-min
dynamic [11C]erlotinib PET scan with arterial and venous sampling at six time points. In patients(E+), the optimal
compartment model was analyzed using Akaike information criterion. In patients(E−), the uptake parameter was the
volume of distribution (VT), estimated by using metabolite-corrected plasma input curves based on image-derived
input functions and discrete arterial and venous blood samples. Tumor blood flow (TBF) was determined by rate
constant of influx (K1) of [15O]H2O using the 1T2k model and correlated with VT and K1 values of [
11C]erlotinib.
The investigated simplified parameters were standardized uptake value (SUV) and tumor-to-blood ratio (TBR) at
40–60 min pi interval.
Results: Of the 13 patients included, ten were scanned twice. In patients(E+), [11C]erlotinib best fitted the 2T4k
model with VT. In all patients, tumor VT(E+) was lower than VT(E−) (median VT(E−) = 1.61, range 0.77–3.01; median
VT(E+) = 1.17, range 0.53–1.74; P = 0.004). Using [
15O]H2O, five patients were scanned twice. TBF did not change with
erlotinib therapy, TBF showed a positive trend towards correlation with [11C]erlotinib K1, but not with VT. TBR40–50
and TBR50–60, using both arterial and venous sampling, correlated with VT(E−) (all rs >0.9, P < 0.001), while SUV did
not. In patients off and on therapy, venous TBR underestimated arterial TBR by 26 ± 12 and 9 ± 9 %, respectively.
Conclusions: In patients on erlotinib in therapeutic dose, tumor VT decreases with high variability, independent of
tumor perfusion. For simplification of [11C]erlotinib PET scanning protocols, both arterial and venous TBR 40–60 min
post injection can be used; however, arterial and venous TBR values should not be interchanged as venous values
underestimate arterial values.
Trial registration: Registered at the Netherlands Trial Registry: NTR3670.
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Background
Non-small cell lung cancer (NSCLC) therapy has entered
an era of precision medicine with an ever-increasing
amount of therapeutic agents directed against specific
tumor targets. Positron emission tomography (PET) is
sometimes used to study the pharmacokinetic behavior of
these new agents and to identify patients that might be
sensitive to these drugs [1]. For this, the molecularly tar-
geting therapeutic agents are labeled with radionuclides to
be used as PET tracers [2].
An important actionable target in NSCLC is the epi-
dermal growth factor receptor (EGFR). EGFR tyrosine
kinase inhibitors (TKIs), such as erlotinib, inhibit growth
in tumors that thrive mainly on the EGFR pathway, such
as tumors with an activating EGFR mutation (EGFRmut)
[3, 4]. PET using carbon-11-labeled erlotinib, [11C]erloti-
nib, allowed to visualize and quantify tumor [11C]erlotinib
uptake in patients with EGFR-mutated NSCLC [1, 5, 6].
Moreover, tumor [11C]erlotinib uptake was shown to be
higher in TKI-sensitive EGFRmut tumors as compared to
tumors with a wild-type EGFR, indicating that PET and
[11C]erlotinib may identify patients that are sensitive to er-
lotinib therapy [1].
Typically, EGFR TKI achieves a median progression-
free survival of approximately 9–10 months in the first
line setting [7]. Ultimately, all EGFRmut patients de-
velop resistance to EGFR TKI during the course of treat-
ment. Various patterns of disease progression may be
observed. In many patients, only a few tumor lesions will
grow, while others remain unchanged. In such oligo-
progressive cases, it is unclear whether EGFR TKI ther-
apy should be discontinued [8]. Decision management
could be guided by knowledge of the residual EGFR TKI
sensitivity of the tumor lesions.
PET using [11C]erlotinib may provide a means to de-
termine residual TKI uptake after disease progression
appears, and consequently, may aid in deciding whether
or not to discontinue EGFR TKI therapy. To answer this
question, PET should preferably be performed during er-
lotinib treatment. However, thus far, [11C]erlotinib PET
scans were performed exclusively in the absence of erlo-
tinib exposure [1, 5, 6]. To be able to interpret [11C]erlo-
tinib PET data of patients in this clinical setting, the
effects caused by the presence of therapeutic concentra-
tions of non-labeled erlotinib on tumor [11C]erlotinib
uptake need to be investigated first. From a tracer phar-
macokinetic perspective, studying the effects of erlotinib
therapy on [11C]erlotinib metabolism, plasma concentra-
tion, and tumor uptake can improve our understanding
of the tracer uptake. These pharmacokinetic insights are
needed for optimization of scanning protocols and de-
sign of future TKI PET studies. At present, the literature
concerning this topic is limited, and to the best of our
knowledge, no other clinical trial scanned patients with
a radiolabeled EGFR TKI during treatment with the
same EGFR TKI.
We performed a pilot study to assess the effect of
pharmacological erlotinib concentrations on tumor [11C]er-
lotinib uptake. The primary objective was to compare
tumor tracer uptake using the gold standard measure
for [11C]erlotinib uptake volume of distribution (VT) in
the presence and absence of pharmacological concen-
trations of erlotinib. The secondary aim of this study
was to assess the effects of erlotinib therapy on tumor
blood flow and its correlation with tumor [11C]erlotinib
uptake. In addition, for simplification of future proto-
cols, we also investigated simplified uptake parameters,
i.e., standardized uptake values (SUVs) and tumor-to-
blood ratio (TBR). TBR was based on arterial samples;
however, we also used venous samples. This was again
important for simplification of future protocols as ar-
terial cannulation could be omitted if venous sampling
was proven to be a valid substitute.
Methods
Patients
Patients with histologically proven EGFRmut NSCLC who
were either planned to initiate erlotinib therapy or to stop
erlotinib therapy due to disease progression while on erlo-
tinib were asked to participate. Key inclusion criteria were
age above 18 years, life expectancy of at least 12 weeks, at
least one tumor lesion with a diameter of at least 1.5 cm
in the chest region as measured by CT, Karnofsky
index >60 %, and a written informed consent. Exclu-
sion criteria were claustrophobia, pregnancy or lactating
patients, metal implants in the thorax (e.g., pacemakers)
that could interfere with PET/CT imaging, and concur-
rent treatment with experimental drugs. The study was
approved by the Medical Ethics Review Committee of the
VU University Medical Center. All patients provided writ-
ten informed consent prior to inclusion.
Study design
The aim was to include ten patients with EGFRmut
NSCLC, who underwent two PET scan sessions. Patients
who were on erlotinib therapy (E+) stopped therapy on
the day of their first scan. Patients who were erlotinib
naïve (E−) started therapy, immediately following the
scanning procedure on day 1. For all patients, a second
PET scan session was performed after 7 to 14 days. All
PET scans were planned to start at the same time of the
day, i.e., at 1:00 p.m. Patients on erlotinib therapy were
asked to take their last medication, i.e., erlotinib 150 mg,
at 8:00 a.m.
PET/CT scanning procedure
One cannula was inserted into the radial artery for arter-
ial blood sampling and another one into a contralateral
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arm vein for tracer injection and venous blood sampling.
Scans were performed on a Gemini TF-64 PET/CT scan-
ner (Philips Medical Systems, Best, the Netherlands),
which is a high performance, time-of-flight (TOF), fully
three-dimensional PET scanner combined with a 64-slice
Brilliance CT scanner [9]. First, 370-MBq [15O]H2O was
injected intravenously, simultaneously starting a 10-min
emission scan. Next, a low-dose CT scan (30 mAs, with-
out contrast) was performed for attenuation correction.
Subsequently, 349 ± 46 MBq of [11C]erlotinib (synthe-
sized as previously described and corresponding to a
non-pharmacological dose of approximately 16.2 μg
“cold” erlotinib with ≥18.5 GBq/μmol specific activity)
was injected intravenously, simultaneously starting a 60-
min emission scan [1]. [15O]H2O and [
11C]erlotinib
emission scans were acquired in list-mode and recon-
structed into 26 frames with progressive increase in
frame duration (1 × 10, 8 × 5, 4 × 10, 2 × 15, 3 × 20, 2 ×
30, and 6 × 60 s) and 36 frames (1 × 10, 8 × 5, 4 × 10, 2 ×
15, 3 × 20, 2 × 30, 6 × 60, 4 × 150, 4 × 300, and 2 × 600 s),
respectively. All appropriate corrections were applied for
dead time, decay, random, scatter, and attenuation. Re-
construction of PET data was performed using the 3D
row-action maximum-likelihood algorithm (RAMLA)
with CT-based attenuation correction. The final voxel size
was 4 × 4 × 4 mm3 and the spatial resolution 5–7 mm full-
width at half-maximum. No corrections for patient mo-
tion were applied.
Arterial and venous samples (7 mL) were taken at six
time points (i.e., at 5, 10, 20, 30, 40, and 60 min) after
injection of [11C]erlotinib. For both arterial and venous
samples, plasma polar [11C]erlotinib metabolites and
whole blood and plasma radioactivity concentrations
were measured, as described previously [1].
Data analysis
For each patient, the primary tumor was identified on
the low-dose CT scan, and the tumor contours were de-
lineated visually at the margins of the tumor on all
planes where the primary tumor was visible, to generate
a three-dimensional tumor volume of interest (VOI).
Large blood vessels and the liver were avoided as much
as possible. We did not delineate tumors on PET, as
[11C]erlotinib PET uptake depends strongly on tumor
characteristics (e.g., EGFR mutation). CT-based contour
delineation was performed using an in-house software,
developed within the interactive data language (IDL Vir-
tual Machine 6.2, RSI Inc., Boulder, CO, USA) environ-
ment. Then, tumor VOIs were projected onto the
dynamic [11C]erlotinib PET scan to generate tumor
[11C]erlotinib time activity curves (TACs). In addition,
metabolite-corrected image-derived plasma input func-
tions (IDIFs) were derived from VOIs drawn on ten subse-
quent slices within the descending aorta (approximately
7 mL). Then, this arterial whole blood TAC was calibrated
by the whole blood activity concentrations measured from
the six manually drawn arterial blood samples. Next, the
data was multiplied by the multi-exponential function that
best fitted the plasma-to-whole blood ratios, again derived
from the manual samples, to generate a plasma TAC.
Then, the plasma TAC was corrected for metabolites
using a sigmoid function derived from the best fit to the
measured parent fractions of the arterial samples. Finally,
a correction for delay was applied; this metabolite-
corrected plasma TAC was used as IDIF [10–12].
A distinction was made in processing the kinetic data
from patients on and off therapy. Previously, in patients
off therapy, the optimal model for tumor [11C]erlotinib
pharmacokinetics was found to be the reversible two-
tissue model (2T4k) [1]. In patients off therapy, all
tumor TACs were analyzed using this model. It was un-
known, however, whether the same model was also valid
for patients on erlotinib therapy. Therefore, in the latter
patients, first, the optimal model was identified by fitting
tumor [11C]erlotinib TACs to three conventional com-
partment models (i.e., single tissue, irreversible two-
tissue, and reversible two-tissue) [10]. Subsequently, the
optimal model was chosen on the basis of the Akaike in-
formation criterion [13]. After establishing the optimal
model for patients on erlotinib therapy, all tumor TACs
were analyzed using the corresponding preferred model.
Pharmacokinetic analysis and modeling of tumor TACs
and IDIF was performed using in-house software, devel-
oped within MATLAB (MathWorks, Inc).
In order to understand the effects of metabolism on
VT values under erlotinib therapy, the change in tumor
VT was correlated with the level of metabolism. As the
level of metabolism, the parent fraction measured at
60 min post injection was used.
For [15O]H2O, same VOIs were drawn on the CT
scans accompanying the [15O]H2O PET scans, and then
projected onto the [15O]H2O data. All tumor TACs were
analyzed with the standard single tissue compartment
model (1T2k) for [15O]H2O [14], resulting in estimates
of tumor blood flow (TBF) as calculated by rate constant
of influx (K1) of [15O]H2O [15].
Simplified analyses
Accuracies of several simplified static approaches were
evaluated. SUVs, normalized for patient weight and
injected dose, were evaluated in the interval 40–50 and
50–60 min. In addition, TBR values were evaluated using
both arterial and venous whole blood activity concentra-
tions in the time interval 40–50 and 50–60 min. These
intervals were chosen, as unpublished analysis of previ-
ous scans showed that TBR using whole blood activity
between 40 and 60 min correlated best with VT [1].
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Statistical analysis
Statistical analysis was performed using SPSS software
(SPSS for Windows 20.0, SPSS, Inc., Chicago, USA) and
GraphPad (GraphPad Prism version 5.00 for Windows,
GraphPad Software, San Diego, CA, USA). Spearman’s
correlation coefficient (rs) and simple linear regression
were used for correlations. A two-tailed probability value
of P < 0.05 was considered to be significant. Bland-
Altman analysis was performed to assess agreement be-
tween venous TBR and arterial TBR, between TBR40–50
and TBR50–60, and between venous and arterial tracer par-
ent fractions. The Wilcoxon matched-pairs signed-rank
test was used to test differences between scans with and
without erlotinib therapy regarding VT values, parent frac-
tion values, whole blood SUVs, and TBF values. This test
was also used to assess differences between whole blood
SUVs obtained with arterial and venous samples.
Results
Patient characteristics
Patient characteristics are shown in Table 1. As three pa-
tients could only be scanned once, a total of 13 patients
were recruited in order to obtain ten patients who were
scanned twice using [11C]erlotinib. In nine out of these
ten patients, both quantitative kinetic analyses could be
obtained. In the remaining patient, this was not possible
due to technical problems with blood sampling. In seven
out of nine evaluable patients, the first [11C]erlotinib PET
scan was without erlotinib therapy. In the remaining two
out of nine patients, the first scan was performed while re-
ceiving erlotinib therapy. In only five out of nine evaluable
patients, both [15O]H2O TBF(E−) and TBF(E+) could be
derived. In the remaining patients, data from both
[15O]H2O PET scans could not be performed or analyzed
due to technical problems, as indicated in Table 1.
Effects of erlotinib therapy on plasma kinetics
Parent fractions of [11C]erlotinib, as measured in arterial
plasma samples, were higher in patients on therapy at all
time points (all P values <0.05, see Fig. 1a). Change in
tracer metabolism during erlotinib therapy did not cor-
relate with changes in VT (rs = 0.33, P = 0.385), as shown
in Fig. 1b.
Arterial blood activity, normalized to injected dose and
patient weight, was also higher in patients on therapy at
all time points (all P values <0.05, Fig. 1c). Detailed results
are shown in Additional file 1: Tables S1 and S2.
Effects of erlotinib therapy on kinetic modeling and
tumor [11C]erlotinib uptake
According to the Akaike information criterion, the revers-
ible two-tissue compartment model (2T4k) was the pre-
ferred model in all patients(E+). This was also the case for
patients(E−), confirming previous findings [1, 5, 6]. In all
nine evaluable patients, tumor [11C]erlotinib VT(E+) was
significantly lower than VT(E−) with a mean (±SD) intra-
patient decrease of 38 ± 13 % (median VT(E−) = 1.61,
range 0.77–3.01; median VT(E+) = 1.17, range 0.53–1.74;
P = 0.004; see Fig. 2a). There was a good correlation be-
tween VT(E+) and VT(E−) (rs = 0.82; P = 0.011), as shown in
Fig. 2b. See Additional file 1: Table S3 for detailed results.
Effects of erlotinib therapy on tumor [15O]H2O perfusion
Tumor [15O]H2O perfusion did not change between pa-
tients on (N = 8) and off (N = 8) erlotinib therapy (with a
mean ± SD TBF of 0.475 ± 0.194 and 0.622 ± 0.397 mL/
cm3/min, P = 0.813, respectively, see Fig. 3a). There was
no correlation between TBF and [11C]erlotinib VT in
patients(E−) and patients(E+) (rs = −0.452, P = 0.268 and
rs = −0.167, P = 0.703, respectively, see Fig. 3b). Tumor
rate constant of [11C]erlotinib influx, i.e., K1, showed a
trend towards positive correlation with TBF(E−) and
TBF(E+); however, this was not statistically significant
(rs = 0.714, P = 0.058 and rs = 0.405, P = 0.327, respect-
ively, see Fig. 3c) (see Additional file 1: Table S4 for
detailed results).
Effects of erlotinib therapy on simplified uptake
parameters
SUVs did not correlate with VT values, both on and off
erlotinib therapy (rs = 0.39, P = 0.260 and rs = 0.30, P =
0.342, respectively). However, TBR40–50 values showed
good correlation with VT values, both on and off therapy
(rs = 0.97, P < 0.001 and rs = 0.96, P < 0.001, respectively),
as shown in Fig. 4. TBR50–60 also showed good correl-
ation (with rs = 0.92, P < 0.001 and rs = 0.99, P < 0.001, re-
spectively). The mean (±SD) difference between TBR40–
50 and TBR50–60 in patients off therapy was 4 ± 7 % and
1 ± 7 % in patients on therapy.
Representative parametric [11C]erlotinib images, using
TBR50–60, of a typical patient off and on erlotinib ther-
apy are shown in Fig. 5.
Arterial versus venous whole blood activity
The mean venous blood activity values, normalized to
injected dose and patient weight, were higher than the
mean arterial values for all measured time points in
patients(E−) (P < 0.05). In patients(E+) at 5 min post in-
jection, the venous values were significantly higher than
arterial values, and at the remaining time points, no dif-
ference was observed. Figure 6a, b illustrates the mean ±
SD whole blood SUV obtained from venous and arterial
samples, in patients off and on erlotinib therapy.
Arterial versus venous metabolites
Metabolite analyses showed a good correlation be-
tween arterial and venous samples (rs = 0.91, P < 0.001
Bahce et al. EJNMMI Research  (2016) 6:10 Page 4 of 13
Table 1 Patient characteristics
Number Gender, age
(years)








b Time interval to second
scan (days)
1 F exon19 (p.delE746-A750) and
exon20 (T790M)
PD First scan E+ Yes Yes Yes
60 (sensitive + resistant) – Second scan E− NA NA NA Synthesis of [11C]erlotinib
failed quality check
7
2 F exon19 (p.delE746-A750) CR First scan E− Yes Yes Yes
82 (sensitive) −52 % Second scan E+ Yes NA Yes No venous sampling due
to clogging of the venous
cannula14
3 M exon18 (p.G719S and p.E709A) PR First scan E− Yes Yes Yes
74 (sensitive [22, 23]) −17 % Second scan E+ Yes Yes NA Synthesis of [15O]H2O failed
quality check
13
4 M exon21 (p.P848L) – First scan E− Yes Yes Yes
66 (resistant [24]) −43 % Second scan E+ Yes Yes Yes
7
5 F exon19 (p.delE746-T751) (sensitive) PD First scan E+ Yes Yes NA Synthesis of [15O]H2O failed
quality check
61 – Second scan NA NA NA NA Yield of [11C]erlotinib
synthesis too low
7
6 F exon19 (p.delE746-A750) and
exon20 (p.T790M)
Slow PD First scan E+ Yes Yes Yes
45 (sensitive + resistant) −47 % Second scan E− Yes Yes Yes
10
7 M exon19 (p.E746-S752) and exon20
(p.T790M)
SD First scan E− NA NA NA Aberrant arterial and venous
blood sample values
74 (sensitive + resistant) – Aberrant [15O]H2O PET data
Second scan E+ Yes Yes Yes
7
8 M exon18 (p.G719S) and exon20
(p.S768I)
SD First scan E− Yes Yes Yes













Table 1 Patient characteristics (Continued)
9 F exon19 (p.delE746-A750) PR First scan E− Yes Yes Yes Aberrant [15O]H2O PET data
55 (sensitive) −29 % Second scan E+ Yes Yes Yes
10
10 F exon19 (p.delL747-S752 and
p.P753Q) and exon20 (p.T790M)
Slow PD First scan E+ Yes Yes NA No [15O]H2O synthesis
71 (sensitive + resistant) −25 % Second scan E− Yes Yes NA No [15O]H2O synthesis
14
11 F exon21 (p.L861Q) SD First scan E− Yes Yes Yes
77 (sensitive [28]) −39 % Second scan E+ Yes Yes NA No [15O]H2O synthesis
7
12 M exon19 (p.delE746 S752) PR First scan E− Yes Yes Yes
70 (sensitive) – Second scan NA NA NA NA Yield of [11C]erlotinib
synthesis too low
7
13 F exon21 (p.L858R) and exon20
(p.T790M)
Slow PD First scan E− Yes Yes Yes
74 (sensitive + resistant) −40 % Second scan E+ Yes Yes Yes
7
Abbreviations: F female, M male, E+ with erlotinib therapy, E− without erlotinib therapy, CR complete response, PR partial response, SD stable disease, PD progressive disease, NA not available
aTumor response to erlotinib as evaluated at the time of the first scan (in patients stopping erlotinib) or tumor response to erlotinib after its initiation (in patients starting erlotinib therapy)












and rs = 0.76, P < 0.001) in patients(E−) and patients(E+),
respectively. There was a good agreement between ar-
terial and venous parent fractions, both off and on er-
lotinib therapy (with an average (±SD) bias of −4.8 ± 4.6
and −0.7 ± 3.5 %, respectively, see Fig. 6c, d).
Arterial versus venous TBR
Only eight out of nine evaluable patients had arterial
and venous sampling in both conditions, i.e., with and
without erlotinib therapy. TBR40–50 values obtained
using arterial and venous blood samples showed good
correlation with each other, both off (rs = 0.95, P < 0.001)
and on (rs = 0.83, P = 0.002) erlotinib therapy. Similar
results were obtained with TBR50–60 (with rs(E−) = 0.89,
P < 0.001 and rs(E+) = 0.93, P < 0.001).
Venous sampling underestimated TBR40–50 as com-
pared to arterial sampling in patients(E−) and patients(E+)
by an average (±SD) of 26 ± 12 and 9 ± 9 %, respectively
(see Fig. 6e, f ). However, venous TBR did have a good
correlation with arterial VT (rs(E−) = 0.90, P < 0.001 and
rs(E+) = 0.79, P = 0.006), as shown in Fig. 4d (see Additional
file 1: Table S5 for individual results).
A B
Fig. 2 Tumor VT values. VT values of all patients without and with erlotinib therapy (a). Correlation between VT with and VT without erlotinib
therapy (b). Abbreviations: VT volume of distribution, E− without erlotinib therapy, E+ with erlotinib therapy
A B
C
Fig. 1 Effect of erlotinib therapy on parent fractions. Comparison of mean (±SD) arterial parent fractions of [11C]erlotinib with and without
erlotinib therapy (a). Correlation of VT change and arterial parent fractions change at 60 min post injection (b). Arterial blood SUV, i.e., activity
normalized to injected dose and patient weight, in patients off and on therapy (c). Abbreviations: VT volume of distribution, SUV standardized
uptake value, E− without erlotinib therapy, E+ with erlotinib therapy
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A B
C D
Fig. 4 Simplified uptake parameters. TBR values from the 40–50-min post injection interval, using arterial samples (a) and SUVs from the 40–50-min
post injection interval (b) in all patients off and on erlotinib therapy. Correlation between TBR values from the 40–50-min post injection interval, using
arterial (c) and venous (d) samples, with VT in all patients off and on erlotinib therapy. Abbreviations: TBR tumor-to-blood ratio, SUV standardized
uptake value, VT volume of distribution, E− without erlotinib therapy, E+ with erlotinib therapy
A B
C
Fig. 3 Tumor blood flow. TBF values of patients without (N = 8) and with (N = 8) erlotinib therapy (a). Correlation of tumor perfusion (TBF) with VT
(b) and [11C]erlotinib K1 (c). Abbreviations: TBF tumor blood flow, VT volume of distribution, E− without erlotinib therapy, E+ with erlotinib
therapy, K1 influx rate constant
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Discussion
Effects of erlotinib therapy on tumor tracer uptake
The present study demonstrated that tumor [11C]erloti-
nib VT decreases significantly during erlotinib therapy.
To our best knowledge, this is the first clinical study
that investigated the change of radiolabeled EGFR TKI
uptake in patients off and on treatment using the same
EGFR TKI. In the presence of therapeutic concentrations
of erlotinib, tumor [11C]erlotinib uptake decreased. This
was presumably caused by occupancy of EGF receptors
by abundantly present non-labeled erlotinib, i.e., due to
a decrease in available binding sites. Blocking studies in
xenograft models provide support for this mechanism.
Using [11C]erlotinib, Petrulli et al. showed that NSCLC
xenografts with activating EGFRmut (HCC827) in mice
had lower tracer uptake when cold erlotinib was given
along with the tracer [16]. In addition, Abourbeh et al.
showed in mice-bearing HCC827 xenografts more than
50 % reduction in tumor [11C]erlotinib uptake after ad-
ministration of excess non-labeled erlotinib [17]. Similar
results were obtained with other radiolabeled TKI, such
as [18F]afatinib [18] and [11C]PD153035 [19]. The fact
that there was consistent decrease in [11C]erlotinib up-
take in the present study supports the notion that up-
take of [11C]erlotinib is, at least in part, due to specific
binding. Furthermore, in the presence of therapeutic
concentrations of erlotinib, obtained by taking a fixed
oral dose of 150 mg erlotinib daily, there was still re-
sidual tumor tracer uptake. Interestingly, from a phar-
macokinetic perspective, this may indicate that there
may be room for increasing the therapeutic concentra-
tion of erlotinib, as at maximal concentration, the spe-
cific binding would be absent.
Erlotinib therapy is known to induce metabolizing en-
zymes, such as CYP1A, CYP3A4, and CYP3A5 [20]. Also,
in vitro data suggest that erlotinib stimulates the metabol-
ism of midazolam in human microsomes, suggesting that
erlotinib could induce its own metabolism and thus also
increase the clearance of [11C]erlotinib [21]. However, this
was not observed in the present study. On the contrary,
parent fractions at 60 min post injection were significantly
higher during erlotinib therapy. Possibly, the presence of
abundant non-labeled erlotinib also saturated the metab-
olizing enzymes, thereby slowing down the metabolism of
[11C]erlotinib. Moreover, patients on therapy had higher
blood activity concentrations, normalized to injected dose
and patient weight. This may also be caused by higher
concentrations of circulating parent tracer due to the
blocking of receptors and enzymes by high concentrations
of non-labeled erlotinib.
Fig. 5 [11C]Erlotinib PET images. PET images of a typical patient (Nr 8), who was scanned first off erlotinib therapy (a); he then started therapy
and was scanned again after 7 days (b). Axial, coronal, and sagittal views are shown, obtained by CT-fused parametrically reconstructed [11C]erlotinib
TBRart,50–60 PET images. The color scale indicates the TBRart,50–60 value per pixel (unitless). The primary tumor lesion (T) and regional lymph nodes (LN)
are clearly visible in the absence of erlotinib therapy. Also, high uptake is seen in the liver (L)
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Among the nine evaluable patients, two were scanned
first under erlotinib therapy and stopped therapy imme-
diately thereafter. In these two patients, the abovemen-
tioned findings were also true, i.e., VT(E+) was lower
than VT(E−) and metabolites(E+) were lower than meta-
bolites(E−). This supports the notion that the presence
of non-labeled erlotinib determined these pharmacoki-
netic changes by the abovementioned mechanism.
High tumor sensitivity to erlotinib could potentially
cause a large decrease in VT. Namely, in the absence of
cold erlotinib, EGFR-TKI-sensitive tumors are expected
to have high [11C]erlotinib VT values as compared to re-
sistant tumors [1]. Once cold erlotinib is added, EGF re-
ceptors become blocked causing VT to drop. The results
of this study confirmed that the patients with the largest
decrease in VT did have responsive tumors; however,
there was no clear association between decrease in VT
and tumor response. To illustrate, three patients (pa-
tients 8, 2, and 6) had a large (i.e., approximately 50 %)
decrease in VT. Patient 8 was treated with erlotinib ther-
apy for a few weeks only. Erlotinib was stopped, as he
refused to continue therapy due to a pneumonia that he
ascribed to erlotinib. He did have some tumor regression
with erlotinib during these few weeks, however, not
enough to be declared a partial response. Patient 2 had a
complete response to erlotinib therapy after 3 months.
Patient 6 had a slow disease progression prior to erloti-




Fig. 6 Arterial and venous sampling. Whole blood SUVs (mean ± SD) obtained from venous and arterial samples, in patients off (a) and on (b)
erlotinib therapy. Bland-Altman plots demonstrating the arterial-venous parent fraction difference (%) per mean parent fraction value in patients
off (c) and on (d) erlotinib therapy. In patients(E−) and patients(E+), a bias of −4.8 ± 4.6 and −0.7 ± 3.5 % was seen, respectively. Dotted lines indicate
the mean bias and the 95 % limits of agreement. Next, Bland-Altman plots demonstrating the arterial-venous TBR40–50 difference (%) per mean VT
value, in ten patients(E−) (e) and 11 patients(E+) (f) that had evaluable arterial and venous TBR values. The horizontal line indicates zero difference
between arterial and venous TBR40–50 measures, values above the zero difference line indicate lower venous TBR40–50 values (i.e., an underestimation).
In patients(E−) and patients(E+), a bias (i.e., average of the differences) of 26 ± 12 and 9 ± 9 % was seen, respectively. Dotted lines indicate the mean bias
and the 95 % limits of agreement. Abbreviations: TBR tumor-to-blood ratio, SUV standardized uptake value, E− without erlotinib therapy, E+ with
erlotinib therapy
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scan but developed a severe flare of her disease within
1 week. Her second scan showed increased tumor vol-
ume and increased VT; this illustrates that her tumor
still had significant amount of sensitive clones. These
cases demonstrate that high decrease in VT can occur in
sensitive tumors; however, there was no clear associ-
ation, that is, responders did not exclusively show high
decrease, as there were two other cases with partial
tumor response to erlotinib therapy who showed moder-
ate decrease in VT of 29 and 17 %. On the other hand,
as a result of erlotinib therapy, changes can occur in the
size of the tumor, its concentration of vital tumor cells
and possibly its EGFR density. These changes can occur
in a period as short as 7 to 14 days after initiation or dis-
continuation of therapy and may also influence VT.
Therefore, any tumor response to erlotinib therapy may
also influence the decrease of VT during therapy. How-
ever, the limited number of patients scanned does not
allow for extensive elaboration. Future studies including
more patients should investigate the correlation between
response and change in uptake.
The decrease in VT varied between 17 and 58 %. This
high level of variability disqualifies VT(E+) as substitute
for VT(E−). Any quantitative comparison between pa-
tients or between different time points in a single patient
should be performed using VT(E−). However, for intra-
patient interlesional comparison at a single time point,
VT(E+) may still be considered. Whether tumor TKI
sensitivity can be predicted by [11C]erlotinib VT(E+) re-
mains to be investigated.
Effect of erlotinib therapy on tumor perfusion
Tumor perfusion was not changed by erlotinib treat-
ment. Also, tumor perfusion showed no association with
[11C]erlotinib VT(E−) nor with VT(E+). However, there
was a positive trend between tumor perfusion and the
delivery of [11C]erlotinib to the tumor, which is in ac-
cordance with the 2T4k model. These findings suggest
that the extraction of [11C]erlotinib remains unchanged
during erlotinib therapy.
Simplified uptake parameters
For simplification of future scanning protocols, SUV was
not found to be a suitable uptake parameter, as it did
not correlate with VT, both on and off therapy. SUV nor-
malizes on the basis of injected dose and patient weight,
which is less accurate as compared to TBR that normal-
izes on the basis of the blood pool activity itself. For
example, during erlotinib therapy, the blood tracer con-
centrations were higher. Due to this increased tracer
availability, the absolute amount of tumor tracer binding
may have changed in varying extent. Tumor SUV does
not take this variable into account, whereas TBR does.
Contrary to SUV, arterial and venous TBR showed an
excellent correlation with arterial VT, supporting the use
of both arterial and venous TBR in the time interval of
40 to 60 min post injection in future whole body static
scanning protocols.
Interestingly, venous TBR values were lower than the
arterial TBR values, especially in patients off therapy.
This was due to higher plasma activity in venous sam-
ples than in arterial samples. As no difference in metab-
olism was observed between venous and arterial
samples, the higher venous plasma activity values were
only caused by a higher venous concentration of parent
molecules. The reason for this finding is unclear. Pos-
sibly, the interstitial compartment together with EGFR
molecules that are highly expressed at the epidermal tis-
sue compartment act as a capacitator, by reversibly bind-
ing [11C]erlotinib molecules. So, venous plasma collects
not only the unbound [11C]erlotinib molecules coming
from the arterio-capillary route but also the [11C]erloti-
nib molecules being released from the interstitial and
peripheral tissue compartments. This can also explain
why patients on therapy, who have more EGFR satur-
ation, have less veno-arterial activity difference. Another
cause that may be considered is the fact that a single
venous cannula was used for tracer injection and blood
withdrawal, which implies that venous activity may in-
crease due to the presence of tracer molecules that
remained sticking to the cannula wall during injection.
However, this mechanism is unlikely as it cannot explain
why the veno-arterial difference was higher in off ther-
apy than on therapy. Nevertheless, venous sampling was
found to be suitable for interlesional quantitative com-
parison using TBR, as long as venous values are not
interchanged together with arterial values.
Limitations
This study was limited by the fact that not all uptake
values of [11C]erlotinib and [15O]H2O and not all arterial
and venous sampling values were present or evaluable in
all patients; this was due to practical limitations as men-
tioned in Table 1. The small number of patients did not
allow to establish the clinical role of [11C]erlotinib PET
during erlotinib therapy. Larger studies are needed to
explore the clinical benefits of scanning during therapy,
e.g., for evaluating interlesional differences within a sin-
gle patient, preferably using TBR as validated in the
current study.
Conclusions
Therapeutically dosed oral erlotinib decreases tumor
[11C]erlotinib VT with high variability, independent of
tumor perfusion. In patients on erlotinib therapy, quan-
titative tracer uptake analysis using VT does not seem
appropriate; however, it may be useful for intrapatient
comparison of tumor lesions, which remains to be
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investigated. For protocol simplification, both arterial
and venous TBR, in the time interval between 40 and
60 min post injection, could be used; however, arterial
and venous TBR values should not be interchanged as
venous values underestimate arterial values.
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Table S2. Whole blood SUV. Table S3. Tumor [11C]erlotinib VT and K1
values. Table S4. Tumor [15O]H2O flow values. Table S5. SUV and TBR
values (unitless). (DOC 170 kb)
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